Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFRESH: Low-Dose Fecal Microbiota Restoration in HIV
NCT03008941Phase 2Completed
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing FMT with Placebo (2 arms). Primary endpoint: Number of participants with treatment-related adverse events at 48 weeks. Started Jan 2017; status: completed.
02
Drugs
fecal microbiome transplant
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03008941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008941.